COVID-19

In this section you will find the HTA reports produced by RedETSA members in response to the COVID-19 pandemic. For additional resources, please visit PAHO’s website.

Limitation of Liability

The information, products, services, tools and/or opinions shared and expressed on the platform are the sole responsibility of the institutions that produce them, and do not necesarily represent the views of PAHO/WHO.

PAHO/WHO and its Specialized Center BIREME make no warranties nor guarantees the accuracy or truthfulness of the information, products, services and/or tools provided. Users must use these products, services and/or tools at their own risk. In no case will PAHO/WHO and its Specialized Center BIREME be liable for damages, even if they may have been warned and/or prevented.

Terms and conditions of use

Results: 1

Metreleptina para pacientes con Lipodistrofia generalizada congénita

Hasdeu, Santiago; Labriola, Cecilia; Villafañe, Daniela; Pícoli, Darío.

INTRODUCCIÓN: Las lipodistrofias pueden ser clasificadas según 1) su origen: congénitas y adquiridas; 2) la pérdida del tejido adiposo: parcial o generalizada. En la literatura, se describen los siguientes tipos: lipodistrofia generalizada adquirida (o síndrome de Lawrence); lipodistrofia parcial ad...

Leptin/analogs & derivatives, Lipodystrophy, Congenital Generalized/drug therapy, Technology Assessment, Biomedical, Cost Efficiency Analysis

Fulltext